← Leaderboards
Glenda E Gray
Wits Health Consortium (Pty), Ltd
$398,868,516
Attributed
$1,094,211,339
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $441M · FY2008–25$500M$375M$250M$125M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,094,211,339 · 3
By mechanism
UM1$1,093,880,374 · 2
R21$330,965 · 1
Top collaborators
- Lawrence Corey27 shared
- Dan H. Barouch19 shared
- Georgia D Tomaras19 shared
- Lerato Mohapi13 shared
- Ravindre Panchia13 shared
- Scott M Hammer7 shared
- Kathleen J Sikkema2 shared
Most similar at Wits Health Consortium (Pty), Ltd
Same institution · by research overlap
- Lerato Mohapi$9,859,668
- Ravindre Panchia$9,859,668
Others in their field
Top investigators on “Hiv Vaccine”
- Lawrence Corey · Fred Hutchinson Cancer Center$780,408,880
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$575,377,030
- Barton F Haynes · Duke University$498,748,538
- Dennis R. Burton · Scripps Research Institute$316,405,695
- Myron S Cohen · Family Health International$228,494,927
- Peter B. Gilbert · Fred Hutchinson Cancer Center$223,794,179
Research focus
Hiv VaccineVaccinesAdultPersonsPreventHiv Vaccine Trials NetworkVaccine TrialSafetyClinical TrialsSiteLeadershipClinical Trials NetworkTransmission ProcessProgramsScientistHiv InfectionsInfectionPreventionUnited States National Institutes Of HealthAids PreventionEfficacy TrialRegimenInfantCommunities
Grant awards (43)
HIV Vaccines Clinical Trials Network Leadership and Operations Center$30,396,659
UM1 · FY2025 · AI
PHRU-Setshaba Clinical Trials Unit$2,946,297
UM1 · FY2025 · AI · contact PI
PHRU-Setshaba Clinical Trials Unit$173,282
UM1 · FY2025 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$21,949,062
UM1 · FY2024 · AI
LOC: HIV Vaccine Trials Network$2,797,660
UM1 · FY2024 · AI
PHRU-Setshaba Clinical Trials Unit$2,607,238
UM1 · FY2024 · AI · contact PI
PHRU-Setshaba Clinical Trials Unit$149,350
UM1 · FY2024 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$38,851,667
UM1 · FY2023 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$19,404,520
UM1 · FY2023 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$2,683,830
UM1 · FY2023 · AI
PHRU-Setshaba Clinical Trials Unit$2,404,119
UM1 · FY2023 · AI · contact PI
CoVPN 3001$305,278
UM1 · FY2023 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$55,953,346
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$34,194,667
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$17,943,267
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$9,754,127
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$6,272,147
UM1 · FY2022 · AI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC$5,663,427
UM1 · FY2022 · AI
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16$5,323,993
UM1 · FY2022 · AI
CoVPN 3001 GY16 PostMerger LOC$3,879,990
UM1 · FY2022 · AI
PHRU-Setshaba Clinical Trials Unit$3,297,099
UM1 · FY2022 · AI · contact PI
CoVPN 3502 A Phase 3, Randomized, Double LOC GY16$293,963
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$61,429,109
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$43,124,622
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$40,320,056
UM1 · FY2021 · AI
PHRU-Setshaba Clinical Trials Unit$3,532,996
UM1 · FY2021 · AI · contact PI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$393,953,893
UM1 · FY2020 · AI
LOC: HIV Vaccine Trials Network$40,823,093
UM1 · FY2020 · AI
KARABELO Clinical Trials Unit for NIAID Networks$6,186,290
UM1 · FY2020 · AI · contact PI
LOC: HIV Vaccine Trials Network$36,148,992
UM1 · FY2019 · AI
KARABELO Clinical Trials Unit for NIAID Networks$3,987,535
UM1 · FY2019 · AI · contact PI
LOC: HIV Vaccine Trials Network$55,377,361
UM1 · FY2018 · AI
KARABELO Clinical Trials Unit for NIAID Networks$1,741,539
UM1 · FY2018 · AI · contact PI
LOC: HIV Vaccine Trials Network$50,375,222
UM1 · FY2017 · AI
KARABELO Clinical Trials Unit for NIAID Networks$1,634,670
UM1 · FY2017 · AI · contact PI
LOC: HIV Vaccine Trials Network$30,221,723
UM1 · FY2016 · AI
KARABELO Clinical Trials Unit for NIAID Networks$918,589
UM1 · FY2016 · AI · contact PI
LOC: HIV Vaccine Trials Network$17,738,847
UM1 · FY2015 · AI
KARABELO Clinical Trials Unit for NIAID Networks$1
UM1 · FY2015 · AI · contact PI
LOC: HIV Vaccine Trials Network$36,427,285
UM1 · FY2014 · AI
KARABELO Clinical Trials Unit for NIAID Networks$2,693,563
UM1 · FY2014 · AI · contact PI
Developing appropriate risk reduction interventions for pre-teens$133,962
R21 · FY2009 · MH · contact PI
Developing appropriate risk reduction interventions for pre-teens$197,003
R21 · FY2008 · MH · contact PI